# Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

> **NCT03709680** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 128 (actual)

## Conditions studied

- Ewing Sarcoma
- Solid Tumors
- Rhabdoid Tumor
- Rhabdomyosarcoma
- Neuroblastoma
- Medulloblastoma
- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Palbociclib
- **DRUG:** Temozolomide
- **DRUG:** Irinotecan
- **DRUG:** Topotecan
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03709680
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-05-24
- **Primary completion:** 2024-08-26
- **Final completion:** 2025-10-18
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2025-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03709680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03709680, "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03709680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*